Genzyme Raises Bid For AnorMED, Emphasizing Market Advantage For Mozobil
This article was originally published in The Pink Sheet Daily
Executive Summary
Latest bid is 12.5% higher than Millennium’s, but the firm will have three days to match it if needed.
You may also be interested in...
Genzyme Wins AnorMED As Millennium Backs Out Of Bidding War
Genzyme gains late-stage product candidate Mozobil for approximately $580 mil.
Genzyme Wins AnorMED As Millennium Backs Out Of Bidding War
Genzyme gains late-stage product candidate Mozobil for approximately $580 mil.
Genzyme Optimistic About Renagel’s Future Despite Fresenius’ Deal For PhosLo
Genzyme CEO does not think Fresenius will inappropriately push physicians to prescribe PhosLo.